|
Delayed
OTC Markets
12:25:32 2026-06-01 EDT
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | +9,900.00% |
|
-.--% | +9,900.00% |
| 12-28 | Motion for Asset Sale Approved for Seelos Therapeutics, Inc. | CI |
| 25-10-21 | GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q). | CI |
Business description: Seelos Therapeutics, Inc.
Number of employees: 8
Sales by Activity: Seelos Therapeutics, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 375K | - | - | - | 2.2M |
Geographical breakdown of sales: Seelos Therapeutics, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
United States | 375K | - | - | - | 2.2M |
Executive Committee: Seelos Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 66 | 2018-12-31 |
| Director of Finance/CFO | 54 | 2021-08-31 | |
Gopal Krishna
CTO | Chief Tech/Sci/R&D Officer | - | - |
Anthony Marciano
IRC | Investor Relations Contact | - | 2018-12-31 |
Company details: Seelos Therapeutics, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9,900.00% | -.--% | +9,900.00% | -100.00% | 136 | |
| -1.38% | +2.23% | +48.54% | +100.96% | 70.24B | |
| -1.04% | -1.22% | +33.27% | +74.98% | 62.63B | |
| -4.43% | -4.37% | -16.56% | +348.82% | 27.36B | |
| +0.16% | +1.53% | +34.92% | +17.47% | 25.71B | |
| -2.27% | -1.95% | -1.16% | -14.43% | 24.83B | |
| +1.61% | -0.69% | +20.85% | -19.42% | 19.52B | |
| +1.26% | -9.06% | +165.21% | +308.08% | 15.51B | |
| -3.91% | -5.71% | -8.71% | +521.92% | 14.66B | |
| -5.56% | +1.04% | -7.81% | +833.69% | 14.69B | |
| Average | +988.44% | -1.20% | +1,016.86% | +207.21% | 27.52B | |
| Weighted average by Cap. | -1.54% | -0.64% | +31.39% | +166.18% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- SEELQ Stock
- Company Seelos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
